RxDoctor Payments Data

David Longley, DO

Family Medicine · Abilene, TXNPI 1023014560

Payments from drug & device makers

$15,266in general payments, 2019–2025

Across 1,223 payments — averaging $12.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Amgen$952
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$15,210100%
  • Education$560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,266 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$202,762
Medicare patients
440
Services billed
7,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide153$151,969
OzempicSemaglutide92$106,195
JardianceEmpagliflozin94$104,326
RybelsusSemaglutide63$90,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$78,213
TrulicityDulaglutide63$68,875
FarxigaDapagliflozin Propanediol68$59,028
EliquisApixaban51$34,640
Breo ElliptaFluticasone/Vilanterol45$23,853
XareltoRivaroxaban24$19,931
VascepaIcosapent Ethyl18$9,671
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,741
JanumetSitagliptin Phos/Metformin Hcl16$8,411
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,383
MyrbetriqMirabegron17$7,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,187$220,845216 claims
Novo NordiskOzempic, Rybelsus$1,868$196,457155 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,381$105,662173 claims
Boehringer IngelheimJardiance$478$104,32694 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,742$67,76980 claims
PfizerEliquis$728$34,64051 claims
Johnson & JohnsonXarelto$108$19,93124 claims
MerckJanumet$171$8,41116 claims
Astellas Pharma US IncMyrbetriq$448$7,68217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →